<Hepatology Digest>: What is the efficacy of current treatment strategies for intermediate and advanced stage HCC, and what are the challenges and limitations associated with them?
In the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), a research study from South Africa found that, despite seldom adhering to antiretroviral therapy (ART), 5 male children who were born with HIV still maintained undetectable viral loads. Researchers believe that due to innate immunological gender differences, boys might have a better chance of achieving sustained virological remission than girls.
<Hepatology Digest>: What role does microbiomics play in the pathogenesis of autoimmune liver diseases? What current research findings have revealed the association between the microbiome and autoimmune liver diseases?
As HIV treatment enters the post-ART era, drug side effects and complications have become significant factors affecting the quality of life for patients. Approximately 20% of patients, after 1-2 years of treatment, have viral loads below the detectable limit, but their CD4 cell count remains below normal levels, leading to poorer clinical outcomes.
On July 23, 2023, the 12th International AIDS Society (IAS) HIV Science Conference, referred to as IAS 2023, officially began in Brisbane, Australia. As one of the largest open academic conferences in the global HIV and AIDS field, the event attracted participation from experts, medical professionals, community groups, and medical enterprises worldwide. The conference emphasized the importance of science as the foundation of policy and practice, highlighting the close integration of science, policy, and activism to promote significant advancements in the HIV and AIDS sector. The theme of the conference is "End Inequalities. End AIDS. End Pandemics.", reflecting IAS's ultimate vision. The goal is to rally health experts globally towards the shared ambition of eradicating AIDS by 2030.
ESMO ASIA 2023 inaugurated its opening session, heralding a landmark event in the world of oncology. Hosted in the prestigious Hall 406, this congress brings together the brightest minds in cancer research and treatment, uniting a global community in the fight against this challenging disease. The opening ceremony featured the traditional Dragon Dance, symbolizing prosperity and health. This cultural performance underscored the congress's commitment to diversity and inclusivity, setting a vibrant tone for the event. After the opening address, ESMO also commended society in Asia for their outstanding contributions in promoting international cooperation and exchanges. Dr. Donglu Zhao accepted the certificate of appreciation on behalf of the Chinese Society of Clinical Oncology (CSCO).
At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".
Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. "Oncology Frontier" has specially invited Professor Yao Zhu from Fudan University's affiliated Cancer Hospital to provide an in-depth interpretation of these research developments.
